Cellectis (CLLS) Free Cash Flow Growth (1y) (2016 - 2026)
Cellectis (CLLS) Free Cash Flow Growth (1y) (2016 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
FCF Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
60.84% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
88.70% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-15.72% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
66.37% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Cellectis |
17.40 Bn |
17.21 Bn |
- |
9.66% |
| Date | Value |
|---|
| Mar 31, 2026 |
9.66% |
| Dec 31, 2025 |
-162.51% |
| Sep 30, 2025 |
92.28% |
| Jun 30, 2025 |
-118.80% |
| Mar 31, 2025 |
27.41% |
| Dec 31, 2024 |
-110.96% |
| Sep 30, 2024 |
69.89% |
| Jun 30, 2024 |
383.48% |
| Mar 31, 2024 |
17.84% |
| Dec 31, 2023 |
854.66% |
| Sep 30, 2023 |
34.44% |
| Jun 30, 2023 |
17.13% |
| Mar 31, 2023 |
21.88% |
| Dec 31, 2022 |
90.26% |
| Sep 30, 2022 |
0.84% |
| Jun 30, 2022 |
-239.39% |
| Mar 31, 2022 |
-9.92% |
| Dec 31, 2021 |
45.49% |
| Sep 30, 2021 |
-33.93% |
| Jun 30, 2021 |
19.04% |
